News of a big and important regulator's move was the electricity that powered Biohaven (NYSE: BHVN) stock to an 11%-plus gain ...

Biohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with ...

Biohaven boasts a robust pipeline with late-stage molecules, but a Hold rating reflects its high market cap and uncertain ...

Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression ...

Biohaven has won Food and Drug Administration priority review for its application seeking approval of troriluzole for adults with spinocerebellar ataxia, a group of rare, genetic neurological ...

In a study published in the journal Current Biology, Johns Hopkins researchers discovered that individual neurons in the ...

As a pro wrestler, Drew McIntyre is one of WWE's biggest and brashest villains. But away from the ring the Ayrshire grappler has a hero close to his heart - his late mum Angela.

Watching his mother get on with life despite suffering from the rare brain condition cerebellar ataxia inspired him to keep going with his own, seemingly unlikely dream of becoming a wrestling star.

Cerebellar patients exhibit various motor impairments, but the sequence of primary and compensatory processes leading to these deficits remains unclear. To investigate this, we reversibly blocked ...